


CLAIMS LISTING

1. (Withdrawn from consideration) Compounds of formula I:



wherein

R^1 = H, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^3$, $-C(O)OR^3$, $-C(O)R^3$, $-CH_2C(O)OR^3$, $-CH_2C(O)NHR^3$, where R^3 is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl;


R^2 = C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X^1 = NHR^4 , where R^4 is H, C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^4 group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the R^4 group further optionally containing one or more halogen atoms.

2. (Withdrawn) The compounds of claim 1, wherein R^1 is H, or C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or $=CH_2$.


3. (Withdrawn) The compounds of claim 2, wherein R^1 is $-CH_3$ or $=CH_2$.

4. (Withdrawn) The compounds of claim 3, wherein the compound is selected from the group consisting of:




5. (Withdrawn) The compounds of claim 1 wherein R^4 is $-\text{CH}_2\text{C}(\text{O})\text{OR}^5$ or $-\text{CH}_2\text{C}(\text{O})\text{NHR}^5$, where R^5 is H, C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

6. (Withdrawn) The compounds of claim 1, wherein the compound is selected from the group consisting of:



7. (Withdrawn) Compounds of formula II:



wherein

R^6 = H, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $-C(O)OR^8$, $-C(O)R^8$,

$-CH_2C(O)OR^8$, $-CH_2C(O)NHR^8$, where R^8 is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl;

R^7 = C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl; and

X^2 = NHR^9 , where R^9 is H, C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^9

group optionally containing a carbonyl group, a carboxyl group, a carboxamide group,

an alcohol group, or an ether group, the R^9 group further optionally containing one or

more halogen atoms;

with the proviso that when R^6 is $-CH_3$, and R^7 is $n-C_{13}H_{27}$, X^2 is not $-NHC_2H_5$.

8. (Withdrawn) The compounds of claim 7, wherein R^6 is C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

9. (Withdrawn) The compounds of claim 8, wherein R^6 is $-CH_3$.

10. (Withdrawn) The compounds of claim 7, wherein R^9 is $-CH_2C(O)OR^{10}$ or $-CH_2C(O)NHR^{10}$, where R^{10} is H, C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.


11. (Withdrawn) Compounds of formula IV:

12. (Withdrawn) The compounds of claim 11, wherein R^{16} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

13. (Withdrawn) The compounds of claim 12, wherein R^{16} is $-CH_3$.

14. (Withdrawn) The compounds of claim 11, wherein R^{19} is $-CH_2C(O)OR^{20}$ or $-CH_2C(O)NHR^{20}$, where R^{20} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

15. (Amended) Compounds of formula V:



wherein

$R^{21} = C_2-C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{23}$, $-C(O)OR^{23}$,

$-C(O)R^{23}$, $-CH_2C(O)OR^{23}$, $-CH_2C(O)NHR^{23}$, where R^{23} is H or C_1-C_{10} alkyl, cycloalkyl, or alkenyl, except when R^{21} is $=CHR^{23}$, R^{23} is not H;


$R^{22} = C_2-C_{20}$ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R^{21} is $-COOH$, then R^{22} is not $-CH_3$, $-nC_5H_{11}$, or $C_{13}H_{27}$, and with the further proviso that when R^{21} is $-CH_2COOH$, then R^{22} is not $-CH_3$, $-CH_2CH_3$, or $-iC_5H_{11}$.

16. The compounds of claim 15. wherein R^{21} is C_2-C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

17. The compounds of claim 16, wherein R^{21} is $=CH_2$.

18. (Withdrawn) Compounds of formula VI:



VI

wherein:


R^{24} = C_2 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $-C(O)OR^{26}$, $-C(O)R^{26}$, $-CH_2C(O)OR^{26}$, $-CH_2C(O)NHR^{26}$, where R^{26} is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl;

R^{25} = C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when R^{24} is $-COOH$, then R^{25} is not $-CH_3$, $-nC_5H_{11}$, or $C_{13}H_{27}$, and with the further proviso that when R^{24} is $-CH_2COOH$, then R^{25} is not $-CH_3$, $-CH_2CH_3$, or $-iC_5H_{11}$.

19. (Withdrawn) The compounds of claim 18, wherein R^{21} is C_2 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

20. (Amended) Compounds of formula VII:




VII

wherein R^{27} = C_3 - C_4 alkyl, C_6 - C_{10} alkyl, C_{12} alkyl, C_{14} alkyl, or C_{16} - C_{20} alkyl.

21. (Cancelled)


22. (Withdrawn) A compound of formula VIII:



VIII

wherein R²⁸ is C₁-C₂₀ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, with the proviso that R²⁸ is not -CH₃, -nC₃H₇, -nC₁₁H₂₃, or -nC₁₃H₂₇.

23. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX:



IX

R^{29} = H, or C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, $=CHR^{31}$, $-C(O)OR^{31}$, $-C(O)R^{31}$, $-CH_2C(O)OR^{31}$, $-CH_2C(O)NHR^{31}$, where R^{31} is H or C_1 - C_{10} alkyl, cycloalkyl, or alkenyl;

R^{30} = C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X^5 = $-OR^{32}$, or $-NHR^{32}$, where R^{32} is H, C_1 - C_{20} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R^{32} group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the R^{32} group further optionally containing one or more halogen atoms;

with the proviso that when R^{29} is $=CH_2$, then X^5 is not OH.











24. (Withdrawn) The pharmaceutical compositions of claim 23, wherein R^{29} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or $=CH_2$.

25. (Withdrawn) The pharmaceutical compositions of claim 24, wherein R^{29} is $-CH_3$ or $=CH_2$.

26. (Withdrawn) The pharmaceutical compositions of claim 23, wherein R^{32} is $-CH_2C(O)OR^{33}$ or $-CH_2C(O)NHR^{33}$, where R^{33} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

27. (Withdrawn) The pharmaceutical compositions of claim 23, where R²⁹ is -C₆H₁₃ or -C₈H₁₇.

28. (Withdrawn) The pharmaceutical compositions of claim 23, wherein the compound is selected from the group consisting of:

		(±) 	
(±) 	(±) 	(±) 	(±) 
 , and	(±) 		

29. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 1.

30. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 7.

31. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 11.


32. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 15.

33. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 18.

34. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 20.

35. A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 22.

36. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to Formula III:.



III

wherein

R¹¹ = H, or C₁-C₂₀ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, =CHR¹³, -C(O)OR¹³, -C(O)R¹³, -CH₂C(O)OR¹³, -CH₂C(O)NHR¹³, where R¹³ is H or C₁-C₁₀ alkyl, cycloalkyl, or alkenyl;

R¹² = C₁-C₂₀ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

X³ = OR¹⁴, where R¹⁴ is C₁-C₂₀ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the R¹⁴ group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the R¹⁴ group further optionally containing one or more halogen atoms.

37. (Withdrawn) The pharmaceutical formulation of claim 36, wherein R^{11} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or $=CH_2$.

38. (Withdrawn) The pharmaceutical formulation of claim 37, wherein R^{11} is $-CH_3$ or $=CH_2$.


39. (Withdrawn) The pharmaceutical formulation of claim 36, wherein R^{14} is $-CH_2C(O)OR^{15}$ or $-CH_2C(O)NHR^{15}$, where R^{15} is C_1 - C_{10} alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

40. (Withdrawn) A method of inducing weight loss in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


41. (Withdrawn) The method of claim 40, wherein the subject is a human.

42. (Withdrawn) The method of claim 40, wherein the subject is an animal.

43. (Withdrawn) The method of claim 41, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:



44. (Withdrawn) The method of claim 42, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:




45. (Withdrawn) A method of inhibiting growth of cancer cells in an animal or human. subject, comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


46. (Withdrawn) The method of claim 45, wherein the subject is a human.

47. (Withdrawn) The method of claim 45, wherein the subject is an animal.

48. (Withdrawn) The method of claim 46, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:



49. (Withdrawn) The method of claim 47, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:




50. (Withdrawn) A method of stimulating the activity of CPT-1 in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


51. (Withdrawn) The method of claim 50, wherein the subject is a human.

52. (Withdrawn) The method of claim 50, wherein the subject is an animal.

53. (Withdrawn) The method of claim 51, wherein the compound is:



54. (Withdrawn) The method of claim 52, wherein the compound is:



55. (Withdrawn) A method of inhibiting the activity of neuropeptide-Y in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.

56. (Withdrawn) The method of claim 55, wherein the subject is a human.











57. (Withdrawn) The method of claim 55, wherein the subject is an animal.

58. (Withdrawn) A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


59. (Withdrawn) The method of claim 58, wherein the subject is a human.

60. (Withdrawn) The method of claim 58, wherein the subject is an animal.

61. (Withdrawn) The method of claim 59, wherein the compound is selected from the group consisting of:

62. The method of claim 60, wherein the compound is selected from the group consisting of:




63. (Withdrawn) A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 23 to said subject.

64. (Withdrawn) The method of claim 63, wherein the subject is a human.

65. (Withdrawn) The method of claim 63, wherein the subject is an animal.

66. (Withdrawn) The method of claim 64, wherein the compound is selected from the group consisting of:



67. (Withdrawn) The method of claim 65, wherein the compound is selected from the group consisting of:

